P722: Results of the STAR study: management of ulcerative colitis in private practice in france, in the first years following diagnosis
ECCO '19 Copenhagen
2019
P723: Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study
ECCO '19 Copenhagen
2019
P724: Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
ECCO '19 Copenhagen
2019
P725: A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience
ECCO '19 Copenhagen
2019
P726: Trough levels of infliximab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn’s disease on infliximab maintenance therapy
ECCO '19 Copenhagen
2019
P727: Quality of life and disease activity in children and adolescents with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P728: Effectiveness and quality of life (QoL) of Ustekinumab (UST) therapy in a Real-world Setting in Germany – First Results of the RUN-CD Study
ECCO '19 Copenhagen
2019
P729: Faecal calprotectin and faecal immunochemical test have different values depending on mucosal status in patients with ulcerative colitis
ECCO '19 Copenhagen
2019
P731: Characteristics and follow-up on body composition, physical activity and quality of life in paediatric patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P732: Endoscopic Balloon Dilation Of Symptomatic Intestinal Crohn’s disease Strictures: Long-Term Data On Efficacy And Safety In A Cohort Of Patients Followed-up For 10 Years
ECCO '19 Copenhagen
2019
P733: Comparative Analysis of Monotherapy and Combination Biological Therapy for Crohn’s disease and ulcerative colitis: Results from a Multi-Country Study in Europe
ECCO '19 Copenhagen
2019
P734: Combining endoscopic and histological activity for predicting response to treatment
ECCO '19 Copenhagen
2019
P736: Characteristics of polymeric formula and mode of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in children with Crohn’s disease
ECCO '19 Copenhagen
2019
P737: SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis
ECCO '19 Copenhagen
2019
P738: The budget impact of early dose optimisation with golimumab in ulcerative colitis in the UK
ECCO '19 Copenhagen
2019
P739: The progression of inflammatory bowel disease throughout Latin America: a systematic review
ECCO '19 Copenhagen
2019
P740: Sexual quality of life in inflammatory bowel disease: a multi-centre, national-level study
ECCO '19 Copenhagen
2019